SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 7, 2016) - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that the U.S. Food and Drug Administration has provided written feedback on the ...
COLUMBUS, Ohio, May 5 Roxane Laboratories, Inc. announcedtoday the approval of its Abbreviated New Drug Application (ANDA) forRopinirole Hydrochloride Tablets, 0.25mg ...
Ropinirole (as HCl) 2mg, 4mg, 6mg, 8mg, 12mg; ext-rel tabs. The precise mechanism of action of ropinirole as a treatment for Parkinson’s disease and RLS is unknown, although it is thought to be ...
Dr. Reddy’s Laboratories announced that it has launched Ropinirole Hydrochloride XR extended-release tablets - 2 mg, 4 mg, 6 mg, 8mg, and 12 mg - a bioequivalent generic version of REQUIP XL tablets ...
May 12, 2005 — The U.S. Food and Drug Administration (FDA) has approved ropinirole HCl tablets for the treatment of moderate to severe primary restless legs syndrome (RLS) in adults, budesonide ...
Drug maker Dr Reddy's Laboratories (DRL) gained over 1% to touch an intraday high of 1,634 on Thursday after company launched Ropinirole Hydrochloride XR tablets in the US. Ropinirole Hydrochloride is ...
Philadelphia, PA (August 1, 2004) – New data published in the August issue of SLEEP shows that patients with primary Restless Legs Syndrome (RLS) and with periodic leg movements during sleep (PLMS), ...
Glenmark Generics Inc., USA (GGI), a subsidiary of Glenmark Generics Limited (GGL), has received ANDA approval from the United States Food and Drug Administration (US FDA) for ropinirole hydrochloride ...
Co announces that the U.S. FDA has accepted for filing the application by its partner, GlaxoSmithKline (GSK), for REQUIP XL 24-Hour Extended-Release Tablets, the proposed brand name for a once-daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback